Home Report Store Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market By Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma] - Forecast to 2030

Report ID:MRHC - 104864 Pages: 150 Jun-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours

The Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market is expected to reach $49.2 billion by 2030 at a CAGR of 8.9% from 2024 to 2030. Pharmaceutical contract development and manufacturing organizations offer various services based on a contract to small or large pharmaceutical companies. These services include active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, drug development & drug discovery services, and biologics manufacturing services. The COVID-19 pandemic positively impacts the pharmaceutical contract development and manufacturing market due to the increased demand for pharmaceutical products such as tablets, capsules, drugs, and vaccines.

The growth of the Asia-Pacific pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, and the rising demand for generic medicines & biologics. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges to the growth of this market.

Complex Manufacturing Requirements of the Pharmaceutical Industry is Driving the Demand for Pharmaceutical Contract Development and Manufacturing Organizations

The pharmaceutical industry is largely driven by scientific discovery, development, and toxicological and clinical experience. Pharmaceutical manufacturing operations may be categorized as primary production of bulk drug substances (APIs) and manufacturing of dosage form products (formulations).

In addition to the complexity of the pharmaceutical manufacturing process, many countries globally have specific legal protections for proprietary drugs and manufacturing processes, known as intellectual property rights. When legal protections are limited or nonexistent, some companies specialize in manufacturing and marketing generic drugs. The pharmaceutical industry requires large capital investments due to the high expenses associated with R&D, regulatory approvals, manufacturing, quality assurance & control, marketing, and sales.

Many countries have extensive government regulations affecting the development and approval of drugs for commercial sale. These countries have strict requirements for good manufacturing practices to ensure the integrity of drug manufacturing operations and pharmaceutical products' quality, safety, and efficacy. These challenges have led pharmaceutical companies to partner with contract manufacturing and development organizations to develop and manufacture pharmaceuticals and biologics, driving the growth of the pharmaceutical contract development and manufacturing market.

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market
Click here to: Get Free Sample Pages of this Report

Rising Demand for Generic Medicines and Biologics

The increasing prevalence of cancer, autoimmune, cardiovascular, and infectious diseases in Asia-Pacific has resulted in the emergence of biopharmaceuticals or biologics as an important therapeutic class for treating these diseases. Biologics offer numerous advantages over synthetic drugs by targeting specific sites and rarely causing side effects, resulting in the increasing number of approvals and the demand for biologics, such as therapeutic proteins and monoclonal antibodies (MAbs).

According to GLOBOCAN, in Asia, the cancer cases in 2020 were 9,503,710 million, which is expected to increase by 59.2% by 2040. Furthermore, the COVID-19 pandemic, the Ebola epidemic, and the rising incidences of infectious diseases significantly burden the healthcare sector and boost the demand for vaccines. For instance, in 2020, the outbreak of the COVID-19 pandemic imposed a huge burden on the pharmaceutical industry and increased the demand for vaccines and breakthrough drugs. Due to this increase, the demand for biopharmaceutical products has risen with the subsequent growth in the Asia-Pacific pharmaceutical contract development and manufacturing market.

Key Findings of the Market Study:

In 2024, the Pharmaceutical Manufacturing Services Segment is Expected to Dominate this Market

Based on type, the Asia-Pacific pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2024, the pharmaceutical manufacturing services segment is expected to account for the largest share of the market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing and the growing demand for generic drugs. Additionally, contract manufacturing organizations conduct the manufacturing process by governing all the environmental and regulatory norms driving the market.

In 2024, the Large Pharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market

Based on end user, the Asia-Pacific pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2024, the large pharmaceutical companies segment is expected to account for the largest share of the market. Factors such as the increasing need for cost control amid increasing pricing pressure, rising complex manufacturing requirements and inclination towards cutting-edge technologies, and sponsors strategically focusing on core business functions such as marketing & R&D support the largest share of the market.

Japan: Fastest Growing Market

Japan is expected to register the highest CAGR during the forecast period. Capacity expansion by key pharmaceutical manufacturers, favorable government regulations supporting the approval of new pharmaceuticals, and the prevalence of chronic illness and other infectious diseases amid the growing geriatric population are the major drivers for the Japanese pharmaceutical contract development and manufacturing market. According to the Population Division, Department of Economic and Social Affairs (DESA), United Nations, in Japan, the percentage of the population aged 65 and above has dramatically increased. It is estimated that this population will account for 37.3% of the total population in Japan by 2030, compared to 23.3% in 2000. This significant growth in the geriatric population has increased the burden of chronic diseases such as cancer and cardiovascular diseases, driving the need for contract development and manufacturing.

Key Players

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the Asia-Pacific pharmaceutical contract development and manufacturing market are Samsung Biologics Co., Ltd. (South Korea), FUJIFILM Diosynth Biotechnologies (Japan), AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Piramal Enterprises Limited (India), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Jubilant Life Sciences Limited (India), IDT Australia (Australia), Nipro Pharma Corporation (Japan), Shanghai ChemPartner Co., Ltd. (China), and Aurobindo Pharma, Ltd. (India).

Scope of the Report:

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment, by Type

Pharmaceutical Manufacturing Services
- Active Pharmaceutical Ingredient (API) Manufacturing Services
- Finished Dosage Forms (FDF) Manufacturing Services
  - Parenteral/Injectable Manufacturing Services
  - Tablet Manufacturing Services
  - Capsule Manufacturing Services
  - Oral Liquid Manufacturing Services
  - Other Formulations
Drug Development Services
Biologics Manufacturing Services
- Active Pharmaceutical Ingredient (API) Manufacturing Services
- Finished Dosage Forms (FDF) Manufacturing Services
  (Note : Other formulations include Topical Formulations, Powders Formulations, and Modified-Release Dosage Forms)

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment, by End User

Large Pharmaceutical Companies
Small & Mid-Size Pharmaceutical Companies
Generic Pharmaceutical Companies

Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment , by Country

China
Japan
India
South Korea
Australia
Singapore
Rest of Asia-Pacific

Key questions answered in the report:

What is the focus of the Asia-Pacific pharmaceutical contract development and manufacturing market?

The Asia-Pacific pharmaceutical contract development and manufacturing market studies different types of services, such as pharmaceutical manufacturing services, drug development services, and biologics manufacturing services used by end users. The Asia-Pacific pharmaceutical contract development and manufacturing market studied in this report involves the analysis of various segments at country levels.

What is the value of revenue generated from pharmaceutical contract development and manufacturing services across the globe?

The Asia-Pacific pharmaceutical contract development and manufacturing market is projected to reach $49.2 billion by 2030 at a CAGR of 8.9% from 2024 to 2030

Which type segment is estimated to hold the major share of the market in 2024?

Among all the types studied in the report, the pharmaceutical manufacturing services segment is expected to account for the largest share of the market in 2024. The largest share of the segment is attributed to the growing need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing and the growing demand for generic drugs.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the Asia-Pacific pharmaceutical contract development and manufacturing market?

The growth of this market is driven by the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, and the rising demand for generic medicines & biologics. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market.

Who are the major players in the Asia-Pacific pharmaceutical contract development and manufacturing market?

The key players operating in the Asia-Pacific pharmaceutical contract development and manufacturing market are Samsung Biologics Co., Ltd. (South Korea), FUJIFILM Diosynth Biotechnologies (Japan), AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Piramal Enterprises Limited (India), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Jubilant Life Sciences Limited (India), IDT Australia (Australia), Nipro Pharma Corporation (Japan), Shanghai ChemPartner Co., Ltd. (China), and Aurobindo Pharma, Ltd. (India)

Which countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

China and Japan are expected to offer significant growth opportunities owing to the government initiatives to create favorable pharmaceutical drug approval programs, increase investment from existing pharmaceutical manufacturers in the country for infrastructure development, and grow investments towards biosimilar manufacturing.

Enquire

Check Discount

Related Tag: Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Contract Development and Manufacturing Contract Manufacturing Organization Pharmaceutical Manufacturing Services Pharmaceutical Outsourcing Pharmaceutical Contract Development and Manufacturing

Processing & Packaging Technologies

Healthcare

1.   Introduction
1.1.   Market Definition
1.2.   Market Ecosystem
1.3.   Currency and Limitations
1.4.   Key Stakeholders
2.   Research Methodology
2.1.   Research Approach
2.2.   Process of Data Collection and Validation
2.2.1.   Secondary Research
2.2.2.   Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3.   Market Sizing and Forecast
2.3.1.   Market Size Estimation Approach
2.3.2.   Growth Forecast Approach
2.3.3.   Assumptions for the Study
3.   Executive Summary
4.   Market Insights
4.1.   Overview
4.2.   Drivers
4.2.1.   Complex Manufacturing Requirements of the Pharmaceutical Industry
4.2.2.   Manufacturers' Growing Inclination Toward the Use of Cutting-Edge Technologies
4.2.3.   Rising Demand for Generic Medicines and Biologics
4.2.4.   Patent Expiration
4.2.5.   Increasing Investments in Pharmaceutical R&D
4.3.   Restraints
4.3.1.   Stringent Regulatory Requirements
4.4.   Opportunities
4.4.1.   Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
4.4.2   Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
4.5.   Challenges
4.5.1.   Shortage of Skilled Professionals
4.5.2.   Introduction of Serialization
4.6.   Trends
4.6.1   Virtual Business Models
4.6.2.   Growing Consolidation Among CDMO Market Players
4.7.   Factor Analysis
4.8.   Regulatory Analysis
4.9.   Porter’s 5 Force Analysis
5.   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment—Type
5.1.   Overview
5.2.   Pharmaceutical Manufacturing Services
5.2.1.   Active Pharmaceutical Ingredient (API) Manufacturing Services
5.2.2.   Finished Dosage Forms (FDF) Manufacturing Services
5.2.2.1.   Parenteral/Injectable Manufacturing Services
5.2.2.2.   Tablet Manufacturing Services
5.2.2.3.   Capsule Manufacturing Services
5.2.2.4.   Oral Liquid Manufacturing Services
5.2.2.5.   Other Formulations
5.3.   Drug Development Services
5.4.   Biologics Manufacturing Services
5.4.1.   Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
5.4.2.   Finished Dosage Form Manufacturing (FDF) Services
6.   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment—by End User
6.1.   Overview
6.2.   Large Pharmaceutical Companies
6.3.   Small & Mid-Size Pharmaceutical Companies
6.4.   Generic Pharmaceutical Companies
7.   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment–by Geography
7.1.   Overview
7.2.   China
7.3.   Japan
7.4.   India
7.5.   South Korea
7.6.   Australia
7.7.   Singapore
7.8.   Rest of Asia Pacific
8.   Competition Analysis
8.1.   Overview
8.2.   Competitive Dashboard
8.2.1.   Industry Leaders
8.2.2.   Market Differentiators
8.2.3.   Vanguards
8.2.4.   Emerging Companies
8.3.   Vendor Market Positioning
8.4.    Market Share Analysis/Market Ranking (2022)
9.   Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, SWOT Analysis for the Top 5 Companies)
9.1.   Samsung Biologics Co., Ltd.
9.2.   FUJIFILM Diosynth Biotechnologies
9.3.   AbbVie Inc.
9.4.   Aenova Group
9.5.   Wuxi Biologics, Inc.
9.6.   Vetter Pharma International GmbH
9.7.   Catalent, Inc
9.8.   Lonza Group Ltd.
9.9.   Recipharm AB
9.10.   Almac Group
9.11.   C.H. Boehringer Sohn Ag & Co. KG.
9.12   Piramal Enterprises Limited
9.13.   Eurofins Scientific
9.14.   Curia Global, Inc.
9.15.   Thermo Fisher Scientific, Inc.
9.16.   Evonik Industries AG
9.17.   Jubilant Life Sciences Limited
9.18.   IDT Australia
9.19.   Nipro Pharma Corporation
9.20   Shanghai ChemPartner Co., Ltd.
9.21.   Aurobindo Pharma, Ltd.
10.   Appendix
10.1.   Available Customization
10.2.   Related Reports

List of Tables
Table 1    Asia-Pacific Pharmaceutical Manufacturing Services Market, by Type, 2021–2030 (USD Million)
Table 2    Asia-Pacific Pharmaceutical Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 3    Asia-Pacific Active Pharmaceutical Ingredient (API) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 4    Asia-Pacific Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2021–2030 (USD Million)
Table 5    Asia-Pacific Finished Dosage Forms (FDF) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 6    Asia-Pacific Parenteral/Injectable Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 7    Asia-Pacific Tablet Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 8    Asia-Pacific Capsule Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 9    Asia-Pacific Oral Liquid Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 10   Asia-Pacific Other Formulations Market, by Country, 2021–2030 (USD Million)
Table 11   Asia-Pacific Drug Development Services Market, by Country, 2021–2030 (USD Million)
Table 12   Asia-Pacific Biologics Manufacturing Services, by Type, 2021–2030 (USD Million)
Table 13   Asia-Pacific Biologics Manufacturing Services, by Country, 2021–2030 (USD Million)
Table 14   Asia-Pacific Active Pharmaceutical Manufacturing Services (API) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 15   Asia-Pacific Finished Dosage Form Manufacturing (FDF) Services Market, by Country, 2021–2030 (USD Million)
Table 16   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 17   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Large Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 18   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Small & Mid-Size Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 19   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Generic Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 20   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Country., 2021-2030 (USD Million)
Table 21   Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 22   Asia-Pacific: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 23   Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 24   Asia-Pacific: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 25   Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 26   China: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 27   China: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 28   China: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 29   China: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 30   China: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 31   Japan: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 32   Japan: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 33   Japan: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 34   Japan: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 35   Japan: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 36   India: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 37   India: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 38   India: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 39   India: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 40   India: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 41   South Korea: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 42   South Korea: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 43   South Korea: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 44   South Korea: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 45   South Korea: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 46   Australia: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 47   Australia: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 48   Australia: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 49   Australia: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 50   Australia: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 51   Singapore: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 52   Singapore: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 53   Singapore: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 54   Singapore: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 55   Singapore: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 56   Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 57   Rest of Asia-Pacific: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 58   Rest of Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 59   Rest of Asia-Pacific: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 60   Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 61   Recent Developments, by Company, 2020—2024

List of Figures
Figure 1   Research Process
Figure 2   Key Secondary Sources
Figure 3   Primary Research Techniques
Figure 4   Key Executives Interviewed
Figure 5   Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6   Market Size Estimation
Figure 7   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2030 (USD Million)
Figure 8   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2030 (USD Million)
Figure 9   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Type, 2024 VS. 2030 (USD Million)
Figure 10   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2024 VS. 2030 (USD Million)
Figure 11   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Country, 2024 VS. 2030 (USD Million)
Figure 12   Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 13   Key Growth Strategies Adopted by Leading Players, 2020—2024
Figure 14   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Competitive Dashboard
Figure 15   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Type
Figure 16   Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Market Share Analysis (2022)
Figure 17   Samsung Biologics Co., Ltd.: Financial Snapshot (2022)
Figure 18   FUJIFILM Diosynth Biotechnologies: Financial Snapshot (2022)
Figure 19   AbbVie Inc.: Financial Snapshot (2022)
Figure 20   Aenova Group.: Financial Snapshot (2022)
Figure 21   Wuxi Biologics, Inc.: Financial Snapshot (2022)
Figure 22   Catalent, Inc.: Financial Snapshot (2022)
Figure 23   Lonza Group Ltd.: Financial Snapshot (2022)
Figure 24   Recipharm AB: Financial Snapshot (2022)
Figure 25   C.H. Boehringer Sohn Ag & Co. KG..: Financial Snapshot (2022)
Figure 26   Piramal Enterprises Limited.: Financial Snapshot (2022)
Figure 27   Eurofins Scientific.: Financial Snapshot (2022)
Figure 28   Thermo Fisher Scientific, Inc., IncFinancial Snapshot (2022)
Figure 29   Evonik Industries AG: Financial Snapshot (2022)
Figure 30   Jubilant Life Sciences Limited: Financial Snapshot (2022)
Figure 31   IDT Australia: Financial Snapshot (2022)
Figure 32   Aurobindo Pharma, Ltd.: Financial Snapshot (2022)